Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
21
datasets available to search
ShareScore release 0.9.0
Dataset results
21 results for “Triptans”
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)
ClinicalTrials.gov study NCT00383162. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)
ClinicalTrials.gov study NCT00382993. IPD Sharing: YES. Countries: 1. Publications: 1.
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
ClinicalTrials.gov study NCT05509400. IPD Sharing: YES. Countries: 15. Publications: 1.
A Cost-Utility Analysis of Oral Triptans for Migraine in an Adult Outpatient Setting in Japan
<p><strong><span>Objectives</span></strong><span><strong>. </strong>Pharmacoeconomic studies have not been performed frequently in Japan. This study attempted to clarify which oral triptans, including eletriptan, naratriptan, rizatriptan, sumatriptan, and zolmitrian, are cost-effective in treating migraine in an adult outpatient setting in Japan.</span></p> <p><strong><span>Methods</span></strong><span><strong>. </strong>A cost-utility analysis was conducted for healthcare payers. The population targeted was Japanese patients over the age of 18 who experienced migraines. A base-case model was prepared using probabilities from a network meta-analysis. Direct costs consisted of medical and drug costs (2017 version). Effectiveness was measured with the EQ-5D-3L questionnaire for adult patients with migraine. The duration of the study was 30 days.</span></p> <p><strong><span>Results</span></strong><span><strong>.</strong> The cost-utility analysis base-case scenario demonstrated that eletriptan, rizatriptan, and sumatriptan were cost-effective from the healthcare payers' perspective. Deterministic sensitivity analyses showed that the results were sensitive to the drug prices of three triptans. A probabilistic sensitivity analysis revealed that eletriptan, rizatriptan, and sumatriptan were acceptable because of their accessibility and the healthcare payer's willingness to pay for them (5,000,000 yen/quality-adjusted life-years) were 0.662, 0.172, and 0.075, respectively.</span></p> <p><strong><span>Conclusions</span><span>.</span> </strong><span>The results revealed that eletriptan, rizatriptan, and sumatriptan are cost-effective treat</span><span>ments</span><span> in Japan </span><span>for </span><span>migraine from a healthcare payer's perspective.</span></p>
Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP)
ClinicalTrials.gov study NCT06267664. IPD Sharing: YES. Countries: 1. Publications: 22.
Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women
ClinicalTrials.gov study NCT05854992. IPD Sharing: NO. Countries: 1. Publications: 2.
Identifying Factors Underlying the Discontinuation of Triptans
ClinicalTrials.gov study NCT00890357. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Sex differences in response to triptans: a systematic review and meta-analysis
Open the record for dataset details and reuse information.
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
ClinicalTrials.gov study NCT06680206. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.
ClinicalTrials.gov study NCT06532357. IPD Sharing: NO. Countries: 1. Publications: 0.
Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
ClinicalTrials.gov study NCT06412965. IPD Sharing: NO. Countries: 1. Publications: 0.
Prescription of Triptans in the Grand Est Region, France
ClinicalTrials.gov study NCT05780580. IPD Sharing: NO. Countries: 1. Publications: 0.
Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans
ClinicalTrials.gov study NCT07177885. IPD Sharing: NO. Countries: 1. Publications: 0.
Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order
ClinicalTrials.gov study NCT00282165. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Impact of Triptan and Doxycycline on Neuroinflammatory Biomarkers in Acute Migraine
ClinicalTrials.gov study NCT01653522. IPD Sharing: NO. Countries: 1. Publications: 0.
Trip-Tox, Effectiveness of Triptans Before and After Onabotulinumtoxin A Treatment in Chronic Migraine
ClinicalTrials.gov study NCT04871152. IPD Sharing: Not stated. Countries: 1. Publications: 0.
TRiptan Use and Serious Vascular Events in Elderly Over 65 Years
ClinicalTrials.gov study NCT02838537. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy
ClinicalTrials.gov study NCT01381497. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
ClinicalTrials.gov study NCT01435941. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data
ClinicalTrials.gov study NCT01381523. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.